Abstract

Proteins are an increasingly important class of drugs used as therapeutic as well as diagnostic agents. A generic physiologically based pharmacokinetic (PBPK) model was developed in order to represent at whole body level the fundamental mechanisms driving the distribution and clearance of large molecules like therapeutic proteins. The model was built as an extension of the PK-Sim model for small molecules incorporating (i) the two-pore formalism for drug extravasation from blood plasma to interstitial space, (ii) lymph flow, (iii) endosomal clearance and (iv) protection from endosomal clearance by neonatal Fc receptor (FcRn) mediated recycling as especially relevant for antibodies. For model development and evaluation, PK data was used for compounds with a wide range of solute radii. The model supports the integration of knowledge gained during all development phases of therapeutic proteins, enables translation from pre-clinical species to human and allows predictions of tissue concentration profiles which are of relevance for the analysis of on-target pharmacodynamic effects as well as off-target toxicity. The current implementation of the model replaces the generic protein PBPK model available in PK-Sim since version 4.2 and becomes part of the Open Systems Pharmacology Suite.

Highlights

  • Whole body physiologically based pharmacokinetic (PBPK) models contain an explicit representation of those organs and tissues that have relevant impact on absorption, distribution, metabolism and elimination (ADME) of a drug [1,2,3,4,5,6,7]

  • A generic physiologically based pharmacokinetic (PBPK) model was developed in order to represent at whole body level the fundamental mechanisms driving the distribution and clearance of large molecules like therapeutic proteins

  • The PBPK model for proteins was built as an extension of the PBPK model for small molecule drugs implemented within the software PK-Sim [33,34,35,36]

Read more

Summary

Introduction

Whole body physiologically based pharmacokinetic (PBPK) models contain an explicit representation of those organs and tissues that have relevant impact on absorption, distribution, metabolism and elimination (ADME) of a drug [1,2,3,4,5,6,7]. The parametrization of PBPK models represents physiological and anatomical information about the organism as well as substance-specific properties of the drug. Therapeutic proteins are an increasingly important class of drugs [9,10,11]. Monoclonal antibodies are used for different indications including cancer, inflammatory and autoimmune diseases [11]. Engineered antibody fragments with tailored pharmacokinetic properties and functionality gain interest as diagnostic and therapeutic agents [9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call